The Definitive Peptide Research Reference Guide — Compound Review

Name: SS-31 Research Peptide
Brand: Purgo Labs
Price: 59.99 USD
Availability: InStock

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

SS-31 Research Guide

SS-31 (Elamipretide) — Szeto-Schiller Mitochondria-Targeting Peptide

Important: The pivotal Phase 3 MMPOWER-3 trial (primary mitochondrial myopathy; Neurology 2023, n≈218) did not meet its primary endpoint. A separate heart failure program (MMPOWER-HF) also did not demonstrate efficacy. Anti-aging and longevity effects are preclinical only. SS-31 is not FDA-approved.

Overview

SS-31 (also known as Elamipretide or MTP-131) is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid essential for electron transport chain function. The proposed mechanism involves stabilizing cardiolipin and restoring cristae architecture. Phase II trials in heart failure showed encouraging signals. The pivotal Phase 3 MMPOWER-3 trial (primary mitochondrial myopathy; Neurology 2023, n≈218) did not meet its primary endpoint. A separate heart failure program (MMPOWER-HF) also did not demonstrate efficacy. Efficacy is not demonstrated in humans. Anti-aging and longevity effects are preclinical only.

Mechanism of Action

SS-31 concentrates in the inner mitochondrial membrane via electrostatic interactions, where it binds cardiolipin — a phospholipid that anchors electron transport chain complexes. By stabilizing cardiolipin, SS-31 maintains optimal cristae architecture and ETC complex conformation, improving ATP synthesis efficiency and reducing electron leak (and consequent ROS generation).

Research Evidence

Phase 2 trials showed encouraging signals; pivotal Phase 3 MMPOWER-3 trial (primary mitochondrial myopathy; Neurology 2023, n≈218) did not meet its primary endpoint
Separate heart failure program (MMPOWER-HF) also did not meet its primary endpoint
Reversed age-related decline in skeletal muscle function in old mice (Science, 2020)
1,000-fold concentration in inner mitochondrial membrane vs. cytoplasm
Reduces mitochondrial ROS by stabilizing cardiolipin and preventing electron leak

Bottom line: SS-31 is a mitochondria-targeted tetrapeptide with a well-characterized mechanism and the most advanced clinical program of any mitochondria-targeted peptide. However, the Phase 3 MMPOWER-3 trial (primary mitochondrial myopathy) failed its primary endpoint, as did the separate MMPOWER-HF heart failure program. Human efficacy is not demonstrated. Anti-aging effects are preclinical only.

Research Protocols & Dosage

Evidence-based research protocols, administration routes, and dosage considerations for SS-31 are detailed in the full compound profile. See also: Dosage guide for SS-31.

Sourcing & Quality

SS-31 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View SS-31 at Purgo Labs.